SCHEMBL1272010

SCHEMBL1272010

CSc1nc(Cl)cc(CS(C)(=O)=O)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.42
ALDH1A1 P00352 3/20 0.40
HTT P42858 2/20 0.39
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
MCL1 Q07820 1/20 0.33
GLP1R P43220 1/20 0.33
CYP3A4 P08684 1/20 0.32
HSP90AA1 P07900 1/20 0.32
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA7 P43166 2/20 0.31
CA13 Q8N1Q1 2/20 0.31
MTOR P42345 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1271969 0.80 ALDH1A1 (0.37) POLBALDH1A1KMT2AMEN1CYP3A4
SCHEMBL1271857 0.79 KMT2A (0.63) POLBALDH1A1HTTKMT2AMEN1
SCHEMBL629436 0.79 ALDH1A1 (0.44) POLBALDH1A1HTTKMT2AMEN1
SCHEMBL10845926 0.78 POLB (0.49) POLBALDH1A1HTTKMT2AMEN1
SCHEMBL26960994 0.77 KMT2A (0.47) POLBALDH1A1HTTKMT2AMEN1
SCHEMBL2462899 0.77 HTT (0.47) POLBALDH1A1HTTKMT2AMEN1
SCHEMBL14399610 0.75 POLB (0.46) POLBHTTKMT2AMEN1GAA
SCHEMBL26961012 0.75 HTT (0.40) POLBALDH1A1HTTKMT2AMEN1
SCHEMBL26961014 0.75 KMT2A (0.45) POLBALDH1A1HTTKMT2AMEN1
SCHEMBL29010137 0.74 POLB (0.41) POLBHTTKMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399302-A1 PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS NATIONAL INSTITUTES OF HEALTH 2023-12-14 US disclosed
EP-2379530-A1 PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER AstraZeneca AB (SE) 2011-10-26 EP disclosed
US-20110053923-A1 CHEMICAL COMPOUNDS 610 ASTRAZENECA (SE) 2011-03-03 US disclosed
US-20110034454-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2011-02-10 US disclosed
WO-2010073034-A1 PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER ASTRAZENECA AB (SE) 2010-07-01 WO disclosed
EP-1979325-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AstraZeneca AB (SE) 2008-10-15 EP disclosed
WO-2007080382-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034454-A1 MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY TYMP, TYMS, PIK3CA POLB 120/4885ALDH1A1 3108/4885HTT 3314/4885
US-20230399302-A1 PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS TST, TYR, STS POLB 175/4885ALDH1A1 2159/4885HTT 598/4885
US-20110053923-A1 CHEMICAL COMPOUNDS 610 ABCG2, CYP3A7, CYP2C19 POLB 2901/4885ALDH1A1 112/4885HTT 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.